Nonexudative (Dry) Age-Related Macular Degeneration (AMD)

Updated: Mar 16, 2017
  • Author: Raj K Maturi, MD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print

Practice Essentials

Nonexudative (dry) age-related macular degeneration (AMD or ARMD) (see the image below) comprises more than 90% of patients diagnosed with AMD. AMD is the most common cause of irreversible vision loss in the developed world. Drusen can be detected early in this disease without visual loss. As dry AMD progresses to retinal atrophy and central retinal degeneration, loss of central vision is often observed. Generally, nonexudative AMD has a much slower (over decades), progressive visual loss relative to exudative (wet) AMD (over months).

Moderate nonexudative age-related macular degenera Moderate nonexudative age-related macular degeneration is shown with the presence of drusen (yellow deposits) in the macular region.

Signs and symptoms

Signs and symptoms of dry AMD include the following:

  • Difficulty with night vision and with changing light conditions (specifically, changes in Amsler grid self-evaluation and trouble with reading)
  • Visual fluctuation (ie, some days, vision is poor; other days, vision appears improved)
  • Difficulty with reading and making out faces
  • Metamorphopsia (distortion of visual images): Not a major patient complaint for dry AMD, but it may be present as the atrophy slowly progresses. However, rapid onset of metamorphopsia is concerning for the development of wet AMD.

See Clinical Presentation for more detail.


Funduscopic examination in patients with suspected AMD includes the following findings:

  • Early to intermediate nonexudative AMD: Significant for the presence of multiple drusen for early AMD. For intermediate AMD, drusen may appear confluent with significant pigment changes and pigment accumulation in the posterior pole. In addition, the retinal pigment epithelium (RPE) often appears atrophic, with easier visualization of the underlying choroid vascular plexus
  • Advanced stages of nonexudative AMD: Coalescence of focal islands of atrophy and formation of large zones of atrophy with severely affected vision
  • Advanced AMD (wet): Choroidal neovascularization: RPE elevation, exudate, subretinal fluid or hemorrhage


  • Fluorescein angiography: Has value in patients with AMD who note a recent onset or worsening of vision associated with metamorphopsia
  • Amsler grid evaluation: Cornerstone of evaluation of nonexudative AMD
  • Ocular coherence tomography (OCT) of the retina
  • Ocular coherence tomography angiography (OCTA) of the retina
  • Slit-lamp biomicroscopy
  • Biopsy and histologic examination

Imaging studies

  • Fundus photography and fundus autofluorescence: Best modality to follow nonexudative AMD
  • Optical coherence tomography (optional; may be used to follow disease progression): To examine retinal thickness
  • Multifocal electroretinography (optional; may be used to follow disease progression): To evaluate functional response of retinal rods and cones

See Workup for more detail.


Prevention is the best treatment for nonexudative AMD, because no satisfactory method exists to treat this condition. Accumulated evidence suggests that AMD is a genetic disease.

Management of exudative AMD may include the following [1] :

  • Intravitreal injection with ranibizumab, bevacizumab, aflibercept, or pegaptanib sodium
  • Photodynamic therapy with verteporfin
  • Thermal laser photocoagulation surgery

Nonpharmacotherapy for both wet and dry AMD

  • Antioxidant vitamin and mineral supplements (vitamin A, vitamin E, zinc, and lutein) [2, 3, 4, 1]
  • Screening for impaired visual acuity
  • Wraparound shades (eg, orange-tinted, blue blocker lenses): Effective solution for delayed dark adaptation and to protect eyes from direct sunlight
  • Avoidance/cessation of tobacco use
  • Frequent follow-up for risk assessment of conversion to exudative AMD

See Treatment and Medication for more detail.



Age-related macular degeneration (AMD or ARMD) is the most common cause of irreversible vision loss in the developed world. AMD is associated with the presence of drusen, without visual loss early in the disease. However, the disease often slowly progresses over years to retinal atrophy and central retinal degeneration with associated loss of central vision. The early form of dry AMD is characterized by small to intermediate sized drusen, without significant vision loss. The intermediate form of dry AMD is associated with loss of retinal pigment epithelium (RPE) and the overlying retinal layers (atrophy), with loss of contrast sensitivity, loss of reading speed, and difficulty with adaptation to changing light conditions. The advanced, nonexudative form of AMD is characterized by the presence of atrophy that can be associated with severe central visual-field loss. In all forms of dry AMD, peripheral visual acuity is preserved. Exudative AMD is associated with the development of choroidal neovascular membranes that result in the development of exudate, subretinal fluid, and hemorrhage, as well as relatively rapid central vision loss and visual distortion.

Greater than 90% of patients diagnosed with AMD have nonexudative (dry) AMD; nonexudative AMD is generally associated with much slower (over decades), progressive visual loss compared with exudative (wet) AMD, which is generally associated with more rapid (over months) visual loss. However, patients with the more advanced cases of dry AMD can have as profound a visual loss as those with exudative AMD.

AMD describes a collection of inherited diseases (multifactorial) that share common features, including age predilection, positive family history, presence of yellow-gray material in the Bruch membrane (ie, drusen), RPE changes (eg, atrophy, clumping, RPE detachments) in the posterior pole or periphery, and visual disturbances (eg, abnormal reading, stereo and/or color vision disturbances, dark/light adaptation disturbances).

RPE degeneration is accompanied by variable loss of both the overlying photoreceptors and the underlying choroidal perfusion. When the appropriate age and clinical findings are accompanied by the loss of visual acuity, visual field, or other visual functions, the condition is often classified as AMD. Early AMD may be diagnosed prior to the onset of visual loss if the patient has characteristic drusen and relevant family history.

AMD usually manifests after age 50 years. The disease is often bilateral and may be asymmetrical, and affected patients report a significant history of disease in family members who have lived to later years of their life. Approximately 10% of patients develop a more rapid form of visual loss secondary to the development of neovascularization from the choroid (CNV), wet AMD. The abnormal vessels may be located either below (type 1) or above (type 2) the RPE. Dry, or nonexudative, AMD is the most prevalent form of this disease. When the dry form of AMD progresses with larger areas of RPE atrophy, the condition is referred to as geographic atrophy (GA). GA usually is bilateral but not necessarily symmetrical. GA can also develop neovascularization and can result in a more rapid loss of vision.

Antioxidant multivitamin therapy (consisting of vitamin A at 25,000 IU, vitamin C at 500 mg, zinc at 80 mg, copper at 2 mg, and vitamin E at 400 mg) has been shown in a large clinical trial, the Age-Related Eye Diseases Study (AREDS), to be helpful in decreasing the risk of visual loss with nonexudative AMD. Most of the decrease in visual loss appeared to result from a reduced risk of conversion to wet AMD. The AREDS notably did not show any benefit with the use of these vitamins in very early AMD or in subjects without AMD at baseline. AREDS also showed a relative increased risk of lung cancer among smokers who used high-dose vitamin A. The AREDS2 study showed that a formulation that replaced vitamin A/beta-carotene with a combination of lutein and zeaxanthin was safer and likely more effective at preventing AMD progression than the initial AREDS formula.

The Women's Antioxidant and Folic Acid Cardiovascular Study looked at a cohort of women without any evidence of AMD. The randomized, double-blind, placebo-controlled trial included 5442 female healthcare professionals and noted that a combination of folic acid (2.5 mg/d), pyridoxine hydrochloride (50 mg/d), and cyanocobalamin (1 mg/d) reduced the relative risk of developing visually significant AMD by approximately 40%. The study also demonstrated a reduced risk of developing non–visually significant AMD by a similar amount. [5]

A phase I study demonstrated visual benefit and decreased progression of AMD in subjects with advanced dry AMD who were provided with an intravitreal implant that secreted ciliary neurotrophic factor (CNTF). Current molecules under investigation aim to inhibit GA progression via various mechanisms, including reducing toxic byproduct generation and accumulation, slowing the visual cycle, and inhibiting the complement pathway, which have all been shown to be involved in the pathogenesis of AMD. Targeting the alternate complement pathway has shown the most promise to date for dry AMD treatment. More specifically, complement factor H mutations have been linked to dry AMD, and smoking, a known risk factor for AMD progression, alters activity of complement factor H. There are both phase 2 and 3 trials underway to address the potential role of complement inhibitors to treat nonexudative AMD.

Additional therapies that have been tried include rheopheresis (apheresis) and laser to drusen. While these therapies demonstrated a small benefit over the short term (1-3 y), they did not prove to have any significant benefit after that time. In fact, the Complications of Age-related Macular Degeneration Prevention Trial (CAPT) has demonstrated that laser to drusen is ultimately not beneficial and may potentially be harmful.



Clinical pathophysiology

The clinical definition of early age-related macular degeneration (AMD or ARMD) varies with the source consulted. A clinically useful guideline is when drusen in the posterior pole are greater than 5 in number and at least 63 µm in size. With time, drusen enlarge and result in shallow elevation of the RPE that overlies the Bruch membrane. These deposits may merge over time, and they can be associated with pigmentation change visible on ophthalmoscopy.

Evaluation of the AREDS results provided a clinically useful method of determining risk of advanced AMD using simple criteria: (1) presence of large drusen (greater than 125 µm in size) and (2) the presence of pigment abnormalities. Thus, one eye having both large drusen and pigment abnormalities has a score of 2 (1 for each criterion), and if both eyes have each risk factor, the score is 4. Using this simplified criteria, the AREDS found that over 5 years, eyes with a risk factor score of 0 had only a 0.4% move to advanced AMD, while those with 1 risk factor had a 3.1% move to advanced AMD. However, when eyes had 2, 3, or 4 risk factors, the rate of advanced AMD conversion (either large geographic atrophy or neovascularization) increased to 12%, 26%, and 47% respectively. [6]

Because the above matrix is a simple and powerful tool to determine the persons who will develop advanced AMD, it is useful to recollect the criteria when performing a clinical examination. For example, the presence of a large druse (125 µm in size) would be most easily remembered by looking for drusen whose shortest diameter is approximately 125 µm (or as large as the diameter of a retinal vein at the optic disc margin). Only drusen within 2 disc diameters of the center were used during the analysis. Pigment abnormalities included any areas of hyperpigmentation or hypopigmentation, as well as noncentral areas of geographic atrophy.

Visual acuity loss or visual-field loss occurs when the RPE atrophies and results in secondary loss of the overlying photoreceptor cells that it supplies. The variety of fundus changes described above defines dry AMD. When the damaged RPE results in the development of choroidal neovascularization with late leakage on fluoresce in angiography and a decrease in vision and metamorphopsia, exudative (wet) AMD is said to occur.

Molecular pathophysiology

Dry AMD is an inherited autosomal dominant disease that appears to be affected by nutrition and environmental factors. Nonexudative AMD is characterized by the degeneration of the retina and the choroid in the posterior pole due to either atrophy or RPE detachment. The atrophy is generally preceded (or coincident in some cases) by the presence of yellow extracellular deposits adjacent to the basal surface of the RPE called drusen.

Drusen are composed of vitronectin (a multifunctional plasma and extracellular matrix protein), lipids, immune and inflammatory related proteins, amyloid associated proteins, as well as other poorly characterized substances. While drusen were thought to be the result of accumulated waste material from subretinal tissues, data now suggest that the accumulation is due to the presence of inflammation in the subretinal space. This extracellular material in the Bruch membrane is composed of various substances, including vitronectin and proteinaceous material. The products of oxidative stress also trigger chronic low-grade inflammation (pathophysiological parainflammation) process in patients with AMD. In early AMD, soft drusen contain many mediators of chronic low-grade inflammation such as C-reactive protein, adducts of the carboxyethylpyrrole protein, immunoglobulins, and acute phase molecules, as well as the complement-related proteins C3a, C5a, C5, C5b-9, CFH, CD35, and CD46. Inappropriate activation of the complement system, mainly alternative pathway, mediates chronic autologous pathophysiological parainflammation in dry and exudative AMD.

The complement system is an alternative system (ie, independent of antibodies) of defense against infection. Complement factor H (CFH) is a robust anti-inflammatory agent, in that it protects host cells from complement-mediated damage by binding to the activated complement component C3b.

In 2005, four separate groups reported that a common variation in the CFH (complement factor H) gene increased susceptibility to dry AMD.

In 2006, two other genes were identified that increased the risk similarly. The CFH polymorphism that was most significantly associated with AMD is a T→C substitution that results in a tyrosine-to-histidine substitution of the CFH protein. Thus, it appears that in affected individuals, RPE cells may undergo damage via the complement system because of their inability to inhibit the complement cascade as effectively. Additional indirect evidence in support of this chain of events is noted by a publication that indicates that choroidal levels of C-reactive protein are elevated in homozygote CFH polymorphic individuals. [7]

Some studies have delineated a molecular pathway leading to geographic atrophy and visual loss. This pathway indicates that RPE death leads to secondary photoreceptor loss and consequent visual loss over time. Ambati et al found that RPE cells in patients with dry AMD have low levels of a RNA-cleaving enzyme, DICER1. Low levels of this enzyme lead to decreased breakdown of RNA-Alu molecules. Overabundance of cytoplasmic RNA-Alu molecules (non-coding sequences of RNA) activates inflammatory proteins (NLRP3 inflammasome), which activates a cascade of molecular responses that lead to RPE cell death. [8, 9]



United States

Age-related macular degeneration (AMD or ARMD) is the leading cause of blindness in the United States for people older than 50 years. The actual frequency of the disease depends on specific racial group studies. AMD is more prevalent in whites and likely has a more severe course in patients who have light-colored eyes. A liberal definition of AMD that includes all patients with significant drusen in the posterior pole, with or without visual loss, estimates the prevalence at greater than 20% of the population older than 60 years. A more rigorous, population-based survey with a definition that requires the presence of either late atrophy and/or choroidal neovascularization results in an incidence of 0% at age 50 years or younger, 2% at 70 years, and 6% at 80 years. In African Americans, dry AMD is noted to be approximately half the incidence rate stated above.


The incidence of AMD in Japanese and other Asian populations is lower than the white population in the United States, but reports suggest that the incidence is increasing. The Inuit people in Greenland have a significantly higher incidence, as well as a distinctive phenotype. Most black Africans and other people with darker-pigmented skin in general have a lower incidence of symptomatic macular degeneration. Similarly, it is evident that the lesions resulting from AMD in Asian populations are different from those in white populations. This is in agreement with the most accepted theory regarding AMD: that it is a multigenic inherited condition. The background and the specific gene affected would affect the phenotype.



Age-related macular degeneration (AMD or ARMD) results in significant visual morbidity. The presence of neovascularization results in a blurry central visual field. Even in dry AMD, with relatively good vision, patients often report trouble adjusting to varying light conditions. Often, these patients note difficulty when initially placed in a dark environment from a relatively lighted one (eg, entering a restaurant from bright sunlight).

AMD patients, especially those with the exudative variant, have a higher incidence of cerebrovascular accidents and cardiac disease.

Geographic atrophy may also be associated with cognitive impairment, as assessed by mini-mental status exams and other similar tests. One case control study demonstrated a 3x increased odds for mild cognitive impairment in geographic atrophy subjects when compared to normal controls even when controlled for age, visual acuity and education level. [10] Additionally, 3000 subjects in the AREDS trial were subject to a battery of cognitive tests. Among subjects with AMD, those with poorer vision had worse cognition. [11] Participants in the Cardiovascular Health Study underwent cognitive testing as well as mini-mental state testing and those with poorer cognition were at a slightly higher risk of having dry AMD. [12] Given the higher rate of impaired cognitive function in patients with dry AMD, it is important for the clinician to consider cognitive function when assessing low vision options and treatments.


The incidence of AMD is higher in whites compared with African Americans. Some studies report a rate of approximately half in African West Indians in Barbados compared with whites in Baltimore, Maryland. The incidence in Asians is between the above 2 rates, although it appears that the incidence is increasing in this population.


No known difference exists between males and females in the incidence of AMD.


As implied by its name, the incidence of AMD is related to the age of the patient. The incidence increases with each decade of life, with a significant rise in patients aged 70 years or older.